Korro Bio (KRRO) Competitors $47.56 -2.14 (-4.31%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends KRRO vs. NAMS, AMPH, AKRO, RXRX, SRRK, MIRM, WVE, CNTA, HRMY, and NRIXShould you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include NewAmsterdam Pharma (NAMS), Amphastar Pharmaceuticals (AMPH), Akero Therapeutics (AKRO), Recursion Pharmaceuticals (RXRX), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), Wave Life Sciences (WVE), Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. Korro Bio vs. NewAmsterdam Pharma Amphastar Pharmaceuticals Akero Therapeutics Recursion Pharmaceuticals Scholar Rock Mirum Pharmaceuticals Wave Life Sciences Centessa Pharmaceuticals Harmony Biosciences Nurix Therapeutics NewAmsterdam Pharma (NASDAQ:NAMS) and Korro Bio (NASDAQ:KRRO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Which has better earnings and valuation, NAMS or KRRO? Korro Bio has lower revenue, but higher earnings than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$33.59M66.72-$176.94MN/AN/AKorro Bio$14.07M31.67-$81.17MN/AN/A Do analysts prefer NAMS or KRRO? NewAmsterdam Pharma presently has a consensus price target of $33.80, indicating a potential upside of 35.74%. Korro Bio has a consensus price target of $142.17, indicating a potential upside of 198.92%. Given Korro Bio's stronger consensus rating and higher probable upside, analysts plainly believe Korro Bio is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media favor NAMS or KRRO? In the previous week, NewAmsterdam Pharma had 8 more articles in the media than Korro Bio. MarketBeat recorded 19 mentions for NewAmsterdam Pharma and 11 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.72 beat NewAmsterdam Pharma's score of 0.57 indicating that Korro Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NAMS or KRRO more profitable? NewAmsterdam Pharma's return on equity of 0.00% beat Korro Bio's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A Korro Bio N/A -50.25%-38.48% Do institutionals and insiders hold more shares of NAMS or KRRO? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 19.5% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 5.4% of Korro Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in NAMS or KRRO? Korro Bio received 4 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes18100.00% Underperform VotesNo VotesKorro BioOutperform Votes22100.00% Underperform VotesNo Votes Which has more volatility and risk, NAMS or KRRO? NewAmsterdam Pharma has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. SummaryNewAmsterdam Pharma beats Korro Bio on 8 of the 15 factors compared between the two stocks. Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Get Korro Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRRO vs. The Competition Export to ExcelMetricKorro BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$445.64M$6.39B$5.07B$8.66BDividend YieldN/A8.08%5.10%4.06%P/E RatioN/A10.92101.9217.46Price / Sales31.67245.131,196.9569.07Price / CashN/A53.4941.0436.36Price / Book2.489.306.345.87Net Income-$81.17M$154.14M$119.64M$225.66M7 Day Performance-32.44%-9.47%-5.13%-1.34%1 Month Performance-40.56%-7.30%-2.72%1.15%1 Year Performance21.98%28.21%31.10%24.02% Korro Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRROKorro Bio2.606 of 5 stars$47.56-4.3%$142.17+198.9%+16.6%$445.64M$14.07M0.0070Earnings ReportAnalyst ForecastAnalyst RevisionNAMSNewAmsterdam Pharma3.0131 of 5 stars$24.69-0.3%N/A+150.5%$2.23B$14.09M0.0057Short Interest ↑News CoverageAMPHAmphastar Pharmaceuticals4.8623 of 5 stars$46.13-3.3%N/A-20.6%$2.22B$644.40M15.381,761Insider SellingAKROAkero Therapeutics4.0236 of 5 stars$31.61-2.4%N/A+94.5%$2.21BN/A-8.4330Earnings ReportShort Interest ↓Analyst RevisionNews CoverageRXRXRecursion Pharmaceuticals2.1201 of 5 stars$7.75+2.2%N/A-7.4%$2.18B$44.58M-5.07400Insider SellingSRRKScholar Rock4.6062 of 5 stars$27.06+1.5%N/A+125.3%$2.17B$33.19M-11.51140Analyst ForecastAnalyst RevisionNews CoverageGap UpMIRMMirum Pharmaceuticals4.3302 of 5 stars$43.58+3.1%N/A+46.8%$2.08B$186.37M-21.57140Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews CoverageWVEWave Life Sciences4.8719 of 5 stars$16.09+1.3%N/A+149.0%$2.01B$110.50M-14.50240Analyst ForecastInsider SellingShort Interest ↑Analyst RevisionNews CoverageCNTACentessa Pharmaceuticals3.8568 of 5 stars$17.49+2.9%N/A+129.2%$1.98B$6.85M-11.2172Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageGap UpHRMYHarmony Biosciences4.8467 of 5 stars$34.46-1.8%N/A+28.5%$1.97B$582.02M16.33200Short Interest ↓NRIXNurix Therapeutics2.6697 of 5 stars$27.50+1.7%N/A+277.6%$1.95B$76.99M-9.45300Positive News Related Companies and Tools Related Companies NewAmsterdam Pharma Alternatives Amphastar Pharmaceuticals Alternatives Akero Therapeutics Alternatives Recursion Pharmaceuticals Alternatives Scholar Rock Alternatives Mirum Pharmaceuticals Alternatives Wave Life Sciences Alternatives Centessa Pharmaceuticals Alternatives Harmony Biosciences Alternatives Nurix Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KRRO) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
